Erasca (ERAS) is moving higher as a near-term “catalyst trade” builds around the company’s upcoming readouts, with investors focused on initial Phase 1 monotherapy data for ERAS-0015 planned for the first half of 2026 and broader expectations that company data could land in Q2 2026. Option flows are also drawing attention, with reports flagging unusually large call activity that can accelerate upside moves when shares start to lift.

Erasca is a clinical-stage oncology developer focused on targeting the RAS/MAPK pathway. In January 2026, the company highlighted early clinical activity for ERAS-0015 in its AURORAS-1 Phase 1 trial, including confirmed and unconfirmed partial responses across tumor types, along with a tolerability profile without dose-limiting toxicities at the evaluated dose levels at that time—setting up 2026 as a year where initial human efficacy and safety signals could define the valuation narrative.

Near-term attention remains on timing and content of the first substantive 2026 data drops, including whether the company provides additional detail around response durability, dose selection, and safety as dose escalation progresses. Investors are also watching competitive context in RAS-targeting drugs and how Erasca’s differentiation case holds up heading into major oncology meeting season, with ASCO 2026 a focal point for potential visibility on new datasets.